UAMS doctor contributes to major ovarian cancer discovery | News
LITTLE ROCK — The Birrer Laboratory at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute helped discover a proteogenomic signature in ovarian cancer that may improve the way the disease is treated around the world.
The discovery, which identifies a 64-protein-gene signature that can predict primary treatment resistance in patients with high grade ovarian cancer, was published Aug. 3 in the journal Cell.
Michael Birrer, M.D., Ph.D., director of the UAMS Winthrop P. Rockefeller Cancer Institute and UAMS vice chancellor, is a senior author on the Cell publication. Birrer, who was the co-principal investigator of the U01 grant from National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, has a laboratory dedicated to the translation of the genomics of ovarian cancer into better treatment of the disease.
Amanda Paulovich, M.D., Ph.D., physician-scientist at Fred Hutchinson Cancer Center and Birrer’s co-author on the study, praised the UAMS team for its work.
“Mike’s decades of experience treating ovarian cancer patients was crucial to ensuring that our project goals and design were crafted to meet the needs of patients with the most devastating form of this disease – platinum refractory ovarian cancers.”
The Birrer Lab helped design, implement, analyze and interpret the results of the study and was critical in assuring the project had sufficient clinically annotated patient specimens for the state of the art proteomic/genomic analysis. The team characterized proteins and genetic markers in 242 high-grade serous ovarian cancers that responded or did not respond to treatment. The tumor samples were collected from patients before they began treatment.
The overall prognosis for women with high grade ovarian cancer is challenging, although the median survival rate has improved to five years. Unfortunately, patients with refractory tumors, those that do not respond to initial therapy, remains unchanged. These patients waste precious time going through initial treatments that do not work.
“Right now, we can’t identify these ovarian cancer patients up front. We find them by default: They get sick and pass away so quickly that they can’t even be put on new clinical trials,” said Birrer. “This study is a huge step forward in that.
“For the first time, we will know if a patient is unlikely to get better with standard treatment and make better recommendations for them to immediately explore other options like new therapeutics in clinical trials.”
Further, the study identifies five subgroups of refractory tumors by specific activated pathways, some of which may be targetable.
The study was led by Paulovich, Birrer and Pei Wang, Ph.D., professor of Genetics and Genomic Sciences at the Icahn School of Medicine in Mount Sinai, NY.
No Byline Policy
Editorial Guidelines
Corrections Policy
Source